-
Image
Oncolipsy at BIOEUROPE 2022
We are proud to participate in this year's BIOEUROPE 2022 in Leipzig, showcasing our Oncolipsy CE-IVD products. It is our great pleasure to be part of the Hellenic Biocluster (HBio) mission, exhibiting along with members of Greek biotech and pharma sectors, in an inviting booth. The HBio presence in BIOEUROPE 2022 is supported by Enterprise Greece.
We are looking forward to seeing you at our booth #66C and scheduling in-person meetings for potential fruitful collaborations.
-
Image
5th ACTC 2021: Advances in circulating tumor cells "Liquid Biopsy in its best", Kalamata, Greece
Pharmassist Ltd was taking part in the "5th Advances in Circulating Tumor Cells: Liquid Biopsy in its best" (ACTC 2021) meeting in Kalamata, proudly introducing our Oncolipsy liquid biopsy diagnostic kits in the field of oncology. After 6 years of hard work, we were privileged to participate with our very own booth in this prominent conference, along with more than 200 Researchers and KOLs on the liquid biopsy field.
-
Image
The EACR Conference on Liquid Biopsies, Bergamo, Italy
We are excited to start out 2022 by joining the Liquid Biopsies EACR conference in Bergamo.
Dates | Tuesday, 24 May, 2022 to Thursday, 26 May, 2022 |
Location | Bergamo, Italy |
Venue | Viale Papa Giovanni XXIII, 106 |
-
Image
Pharmassist is funded by “Competitiveness, Entrepreneurship and Innovation” (EPAnEK) for the development of innovative technologies
Pharmassist is funded by the “Competitiveness, Entrepreneurship and Innovation” (EPAnEK) Operational Program for the development of innovative technologies regarding the detection of predictive cancer biomarkers by liquid biopsy approach. Pharmassist’s objective is the development and commercialization of in-vitro diagnostics, establishing the liquid biopsy into clinical practice. In this project, namely CANCER blood scan, Pharmassist will collaborate with the ACTC Lab of the National and Kapodistrian University of Athens along with pronounced University Oncological Clinical Centers.